{
  "id": "sequoia:genedit",
  "sequoia_id": null,
  "name": "GenEdit",
  "slug": "genedit",
  "description": "GenEdit wants to transform the delivery of gene therapies for the next generation of non-viral, gene editing-based therapeutics. GenEditâ€™s technology platform solves delivery challenges by systematically screening its proprietary nanoparticle library and providing safe, efficient delivery to target tissues. Its proprietary nanoparticles have broad applications, from CRISPR-based therapeutics to gene therapy products.",
  "website": "https://www.genedit.com/",
  "socials": {
    "linkedin": "https://www.linkedin.com/company/genedit/about/"
  },
  "categories": [
    "healthcare"
  ],
  "current_stage": null,
  "first_partnered_year": 2016,
  "partners": [
    "roelof-botha"
  ],
  "primary_partner": "roelof-botha",
  "milestones": {
    "founded_year": 2016,
    "partnered_year": 2016,
    "ipo_year": null,
    "acquired_year": null
  },
  "team": [
    {
      "name": "Kunwoo Lee",
      "role": null
    },
    {
      "name": "Niren Murthy",
      "role": null
    },
    {
      "name": "Hyo Min Park",
      "role": null
    }
  ],
  "why_partnered": null,
  "source_urls": {
    "directory": "https://sequoiacap.com/our-companies/",
    "profile": "https://sequoiacap.com/companies/genedit/"
  }
}
